Reaction
Radiation Skin Injury reporting signals
As of the last recalculation, Radiation Skin Injury appears in 1,146 FAERS reports alongside 38 co-occurring drug terms. The strongest observed disproportionality signal is CETUXIMAB (PRR 151.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Cetuximab | 213 | 151.4 | 152.5 |
| Ado-Trastuzumab Emtansine | 22 | 48.3 | 48.4 |
| Vemurafenib | 30 | 46.5 | 46.6 |
| Pertuzumab | 55 | 38.5 | 38.6 |
| Cisplatin | 126 | 32.8 | 32.8 |
| Docetaxel Anhydrous | 98 | 28.8 | 28.8 |
| Docetaxel | 98 | 28.8 | 28.8 |
| Capecitabine | 112 | 24.5 | 24.6 |
| Trastuzumab | 81 | 23.0 | 23.0 |
| Fluorouracil Cream, 0.5% | 87 | 22.3 | 22.4 |
| Fluorouracil | 87 | 22.0 | 22.0 |
| Exemestane | 20 | 17.2 | 17.3 |
| Granisetron Hydrochloride | 9 | 15.8 | 15.8 |
| Paclitaxel (Aibumin-Bound) | 67 | 15.7 | 15.7 |
| Paclitaxel | 76 | 14.9 | 14.9 |
| Gefitinib | 7 | 14.2 | 14.2 |
| Letrozole | 46 | 14.1 | 14.1 |
| Carboplatin | 91 | 14.0 | 14.1 |
| Granisetron | 8 | 13.9 | 14.0 |
| Letrozole Tablets | 35 | 13.6 | 13.6 |
| Dabrafenib | 15 | 13.1 | 13.1 |
| Anastrozole | 25 | 12.6 | 12.6 |
| Minocycline | 8 | 12.5 | 12.6 |
| Fosaprepitant Dimeglumine | 9 | 12.0 | 12.0 |
| Erlotinib Hydrochloride | 8 | 11.7 | 11.7 |
| Aprepitant | 11 | 10.9 | 10.9 |
| Conjugated Estrogens And Medroxyprogesterone Acetate | 14 | 10.9 | 10.9 |
| Lapatinib | 9 | 10.6 | 10.6 |
| Panitumumab | 9 | 10.5 | 10.5 |
| Ribociclib | 18 | 10.5 | 10.5 |
| Oxaliplatin | 38 | 9.6 | 9.6 |
| Erlotinib | 5 | 9.4 | 9.4 |
| Polatuzumab Vedotin | 5 | 9.3 | 9.3 |
| Temozolomide | 9 | 7.8 | 7.8 |
| Abemaciclib | 8 | 7.3 | 7.3 |
| Ipilimumab | 16 | 6.8 | 6.8 |
| Nivolumab | 33 | 6.4 | 6.4 |
| Medroxyprogesterone Acetate | 15 | 5.5 | 5.5 |